GRAIL is trading 4.91% lower at $132.60, with available coverage identifying no specific catalyst for the decline.
- The decline runs counter to the supplied positive broader-market and biotech-sector context, neither of which clearly explains the move.
- Third-quarter results are scheduled for after the market close on November 4, 2026; they are not reported results driving the decline.